Details of the Drug

General Information of Drug (ID: DM9OZWQ)

Drug Name
Lovastatin
Synonyms
lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination
Indication
Disease Entry ICD 11 Status REF
Hypercholesterolaemia 5C80.0 Approved [1], [2]
Cardiovascular disease BA00-BE2Z Phase 3 [3]
Therapeutic Class
Anticholesteremic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 404.5
Topological Polar Surface Area (xlogp) 4.3
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 3.013 mcg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3.36 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Elimination
Following an oral dose of 14C-labeled lovastatin to man, 10% of the dose was excreted in urine and 83% in feces [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 13.37 hours [4]
Metabolism
The drug is metabolized via serum paraoxonase [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.28759 micromolar/kg/day [8]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0004 mg/mL [5]
Chemical Identifiers
Formula
C24H36O5
IUPAC Name
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
Canonical SMILES
CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
InChI
InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey
PCZOHLXUXFIOCF-BXMDZJJMSA-N
Cross-matching ID
PubChem CID
53232
ChEBI ID
CHEBI:40303
CAS Number
75330-75-5
DrugBank ID
DB00227
TTD ID
D06WTZ
VARIDT ID
DR00410
INTEDE ID
DR0986
ACDINA ID
D00377

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [13]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [13]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [13]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [13]
Serum paraoxonase/lactonase 3 (PON3) DETXQZ1 PON3_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypercholesterolaemia
ICD Disease Classification 5C80.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HMG-CoA reductase (HMGCR) DTT HMGCR 1.01E-05 0.65 1.53
P-glycoprotein 1 (ABCB1) DTP P-GP 3.29E-14 -7.08E-01 -1.99E+00
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 3.27E-01 -5.78E-02 -3.84E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 2.00E-01 5.79E-02 3.00E-01
Serum paraoxonase/lactonase 3 (PON3) DME PON3 2.30E-02 -3.44E-01 -1.20E+00
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.47E-02 -1.13E-01 -1.13E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 4.03E-02 -1.19E-01 -5.11E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.24E-05 -3.48E-01 -1.34E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lovastatin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Bempedoic acid DM1CI9R Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [80]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Lovastatin and Mipomersen. Hyper-lipoproteinaemia [5C80] [81]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Lovastatin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [82]
BMS-201038 DMQTAGO Major Decreased metabolism of Lovastatin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [83]
Coadministration of a Drug Treating the Disease Different from Lovastatin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [84]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Thioguanine. Acute myeloid leukaemia [2A60] [85]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Lovastatin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [86]
Midostaurin DMI6E0R Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [87]
Idarubicin DMM0XGL Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [88]
Daunorubicin DMQUSBT Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [88]
Arn-509 DMT81LZ Moderate Increased metabolism of Lovastatin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [87]
Emapalumab DMZG5WL Moderate Altered metabolism of Lovastatin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [87]
Siltuximab DMGEATB Moderate Altered metabolism of Lovastatin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [87]
Ranolazine DM0C9IL Major Decreased metabolism of Lovastatin caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [87]
Dronedarone DMA8FS5 Major Decreased metabolism of Lovastatin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [89]
Nifedipine DMSVOZT Moderate Decreased metabolism of Lovastatin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [90]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [91]
Voriconazole DMAOL2S Major Decreased metabolism of Lovastatin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [92]
Posaconazole DMUL5EW Major Decreased metabolism of Lovastatin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [84]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Lovastatin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [90]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Lovastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [93]
Clarithromycin DM4M1SG Major Decreased metabolism of Lovastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [92]
Telithromycin DMZ4P3A Major Decreased metabolism of Lovastatin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [94]
Ag-221 DMS0ZBI Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [84]
Erdafitinib DMI782S Moderate Increased metabolism of Lovastatin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [95]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Lovastatin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [96]
Talazoparib DM1KS78 Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [97]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Lovastatin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [90]
Tucatinib DMBESUA Major Decreased metabolism of Lovastatin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [98]
Palbociclib DMD7L94 Moderate Decreased metabolism of Lovastatin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [90]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Lovastatin caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [90]
Mifepristone DMGZQEF Major Decreased metabolism of Lovastatin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [99]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Lovastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [90]
Lumacaftor DMCLWDJ Major Increased metabolism of Lovastatin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [84]
Ivacaftor DMZC1HS Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [100]
MK-8228 DMOB58Q Major Decreased clearance of Lovastatin due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [101]
Aprepitant DM053KT Moderate Decreased metabolism of Lovastatin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [90]
Nefazodone DM4ZS8M Major Decreased metabolism of Lovastatin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [98]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Lovastatin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Stiripentol DMMSDOY Moderate Decreased metabolism of Lovastatin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [103]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Cannabidiol. Epileptic encephalopathy [8A62] [87]
Itraconazole DMCR1MV Major Decreased metabolism of Lovastatin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [82]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Lovastatin caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [87]
Miconazole DMPMYE8 Moderate Decreased metabolism of Lovastatin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [87]
Ketoconazole DMPZI3Q Major Decreased metabolism of Lovastatin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [104]
Omeprazole DM471KJ Moderate Increased plasma concentrations of Lovastatin and Omeprazole due to competitive inhibition of the same metabolic pathway. Gastro-oesophageal reflux disease [DA22] [105]
Cimetidine DMH61ZB Moderate Decreased metabolism of Lovastatin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [90]
Boceprevir DMBSHMF Major Decreased metabolism of Lovastatin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [92]
Simeprevir DMLUA9D Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [106]
Telaprevir DMMRV29 Major Decreased metabolism of Lovastatin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [92]
Rifampin DMA8J1G Major Accelerated clearance of Lovastatin due to the transporter induction by Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [105]
Rifapentine DMCHV4I Moderate Increased metabolism of Lovastatin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [107]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [108]
Delavirdine DM3NF5G Major Decreased metabolism of Lovastatin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [109]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Lovastatin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Fostemsavir DM50ILT Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [111]
Nevirapine DM6HX9B Moderate Increased metabolism of Lovastatin caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [112]
Cobicistat DM6L4H2 Major Decreased metabolism of Lovastatin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Tipranavir DM8HJX6 Major Decreased metabolism of Lovastatin caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Efavirenz DMC0GSJ Moderate Increased metabolism of Lovastatin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [112]
Saquinavir DMG814N Major Decreased metabolism of Lovastatin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Etravirine DMGV8QU Moderate Increased metabolism of Lovastatin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [113]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Lovastatin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [114]
Amprenavir DMLMXE0 Major Decreased metabolism of Lovastatin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Darunavir DMN3GCH Major Decreased metabolism of Lovastatin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Atazanavir DMSYRBX Major Decreased metabolism of Lovastatin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Ritonavir DMU764S Major Decreased metabolism of Lovastatin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [110]
Levamlodipine DM92S6N Moderate Decreased metabolism of Lovastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Diltiazem DMAI7ZV Major Decreased clearance of Lovastatin due to the transporter inhibition by Diltiazem. Hypertension [BA00-BA04] [90]
Amlodipine DMBDAZV Moderate Decreased metabolism of Lovastatin caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [90]
Conivaptan DM1V329 Major Decreased metabolism of Lovastatin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [92]
Tolvaptan DMIWFRL Minor Decreased metabolism of Lovastatin caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [115]
Lesinurad DMUR64T Moderate Increased metabolism of Lovastatin caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [116]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Lovastatin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [90]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Lovastatin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [90]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Methotrexate. Leukaemia [2A60-2B33] [87]
Crizotinib DM4F29C Moderate Decreased metabolism of Lovastatin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [90]
Brigatinib DM7W94S Moderate Increased metabolism of Lovastatin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [117]
Ceritinib DMB920Z Major Decreased metabolism of Lovastatin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [98]
PF-06463922 DMKM7EW Moderate Increased metabolism of Lovastatin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [118]
Osimertinib DMRJLAT Moderate Increased metabolism of Lovastatin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [87]
Selpercatinib DMZR15V Moderate Decreased metabolism of Lovastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [90]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [119]
Idelalisib DM602WT Major Decreased metabolism of Lovastatin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [98]
IPI-145 DMWA24P Moderate Decreased metabolism of Lovastatin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [90]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Clofarabine. Mature B-cell lymphoma [2A85] [120]
Arry-162 DM1P6FR Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Arry-162. Melanoma [2C30] [84]
LGX818 DMNQXV8 Moderate Increased metabolism of Lovastatin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [121]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Lovastatin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [84]
Danazol DML8KTN Major Decreased metabolism of Lovastatin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [93]
Exjade DMHPRWG Moderate Decreased metabolism of Lovastatin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [122]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Lovastatin and Thalidomide. Multiple myeloma [2A83] [114]
Bexarotene DMOBIKY Moderate Increased metabolism of Lovastatin caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [87]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Lovastatin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [90]
Nilotinib DM7HXWT Moderate Decreased metabolism of Lovastatin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [90]
Imatinib DM7RJXL Moderate Decreased metabolism of Lovastatin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [90]
Dasatinib DMJV2EK Moderate Decreased metabolism of Lovastatin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [90]
Modafinil DMYILBE Moderate Increased metabolism of Lovastatin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [84]
Netupitant DMEKAYI Moderate Decreased metabolism of Lovastatin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [93]
Entrectinib DMMPTLH Moderate Decreased metabolism of Lovastatin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [90]
Olaparib DM8QB1D Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Olaparib. Ovarian cancer [2C73] [84]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Lovastatin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [90]
Abametapir DM2RX0I Moderate Decreased metabolism of Lovastatin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [123]
Esomeprazole DM7BN0X Moderate Increased plasma concentrations of Lovastatin and Esomeprazole due to competitive inhibition of the same metabolic pathway. Peptic ulcer [DA61] [105]
Lefamulin DME6G97 Moderate Decreased metabolism of Lovastatin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [124]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Lovastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [125]
Enzalutamide DMGL19D Moderate Increased metabolism of Lovastatin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [126]
Darolutamide DMV7YFT Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [87]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Lovastatin caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [90]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Lovastatin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [87]
Ixekizumab DMXW92T Moderate Altered metabolism of Lovastatin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [87]
Bosentan DMIOGBU Moderate Increased metabolism of Lovastatin caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [127]
Tocilizumab DM7J6OR Moderate Altered metabolism of Lovastatin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [87]
Canakinumab DM8HLO5 Moderate Altered metabolism of Lovastatin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [87]
Rilonacept DMGLUQS Moderate Altered metabolism of Lovastatin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [87]
Golimumab DMHZV7X Moderate Altered metabolism of Lovastatin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [87]
Sarilumab DMOGNXY Moderate Altered metabolism of Lovastatin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [87]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Lovastatin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [90]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Lovastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [87]
Larotrectinib DM26CQR Moderate Decreased metabolism of Lovastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [90]
Armodafinil DMGB035 Moderate Increased metabolism of Lovastatin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [84]
LEE011 DMMX75K Moderate Decreased metabolism of Lovastatin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [90]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Naltrexone. Substance abuse [6C40] [128]
Fostamatinib DM6AUHV Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [129]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [130]
Brilinta DMBR01X Moderate Decreased metabolism of Lovastatin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [87]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Lovastatin and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [131]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Lovastatin and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [131]
Amiodarone DMUTEX3 Major Decreased metabolism of Lovastatin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [132]
⏷ Show the Full List of 125 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Acetyltributyl citrate E00127 6505 Plasticizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lovastatin 20 mg tablet 20 mg 24 HR Extended Release Oral Tablet Oral
Lovastatin 40 mg tablet 40 mg 24 HR Extended Release Oral Tablet Oral
Lovastatin 60 mg tablet 60 mg 24 HR Extended Release Oral Tablet Oral
Lovastatin 10 mg tablet 10 mg Oral Tablet Oral
Lovastatin 40 mg tablet 40 mg Oral Tablet Oral
Lovastatin 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2739).
2 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
3 Clinical pipeline report, company report or official report of CardioPharma Wilmington.
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 BDDCS applied to over 900 drugs
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C: Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
10 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
11 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
12 Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
13 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
14 Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
25 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
26 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
27 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
28 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
29 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
30 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
31 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
32 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
33 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
34 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
35 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
36 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
37 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
38 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
39 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
40 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
41 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
42 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
43 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
44 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
45 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
46 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
47 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
48 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
49 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
50 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
51 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
52 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
53 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
54 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
55 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
56 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
57 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
58 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
59 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
60 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
61 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
62 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
63 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
64 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
65 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
66 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
67 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
68 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
69 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
70 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
71 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
72 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
73 FDA Drug Development and Drug Interactions
74 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
75 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
76 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
77 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
78 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
79 Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo). 2002 Oct;48(5):332-7.
80 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
81 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
82 Canadian Pharmacists Association.
83 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
84 Cerner Multum, Inc. "Australian Product Information.".
85 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
86 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
87 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
88 Multum Information Services, Inc. Expert Review Panel.
89 Holtzman CW, Wiggins BS, Spinler SA "Role of P-glycoprotein in statin drug interactions." Pharmacotherapy 26 (2006): 1601-7. [PMID: 17064205]
90 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
91 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
92 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
93 Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
94 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
95 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
96 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
97 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
98 Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
99 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
100 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
101 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
102 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
103 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
104 Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
105 Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
106 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
107 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
108 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
109 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
110 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
111 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
112 Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
113 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
114 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
115 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
116 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
117 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
118 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
119 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
120 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
121 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
122 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
123 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
124 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
125 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
126 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
127 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
128 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
129 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
130 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
131 Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
132 Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1. [PMID: 16159992]